billHR7994Event Thursday, June 25, 2026Analyzed

HERO Act

Bullish

Summary

The HERO Act (HR 7994) would establish a grant program for schools to purchase opioid overdose reversal drugs, boosting demand for naloxone manufacturers like Emergent BioSolutions. The bill has been forwarded by subcommittee to full committee, indicating some momentum, but no specific funding amount is authorized.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.The HERO Act aims to increase naloxone availability in schools through a grant program.
  • 2.Emergent BioSolutions ($EBS) is the primary manufacturer of Narcan, the most widely used opioid overdose reversal drug.
  • 3.The bill is still in committee; no funding amount is specified, so the impact is modest and contingent on future appropriations.

Market Implications

The bill's progress is a positive signal for the opioid reversal drug market, particularly for $EBS. However, without a specific authorized funding level, the near-term revenue impact is uncertain. The stock may see modest upward pressure on legislative momentum, but significant gains require passage and appropriation.

Full Analysis

The HERO Act, introduced by Rep. Ruiz, would create a competitive grant program through HHS to help schools purchase FDA-approved opioid overdose reversal drugs (primarily naloxone) and develop educational programming. The bill was forwarded by the Subcommittee on Health to the full Committee on Energy and Commerce on June 25, 2026, via voice vote. It is still in the early legislative stages and has not yet been voted on by the full House or Senate. The bill does not specify an authorized funding amount, meaning actual appropriations would be determined separately. The primary beneficiaries are naloxone manufacturers, with Emergent BioSolutions ($EBS) being the leading producer of Narcan. The bill also requires schools receiving federal funds to report any distribution of opioid reversal drugs, which marginally increases administrative burden on schools but does not have direct market impact. The legislative path forward includes consideration by the full Energy and Commerce Committee, then the House floor, and potentially Senate action. Given the bipartisan nature of opioid-related legislation, the bill has moderate chances of eventual passage, but the lack of a specific dollar amount limits near-term revenue visibility.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$EBS▲ Bullish
Est. $5.0M$20.0M revenue impact

What the bill does

Grant program authorized for schools to purchase opioid overdose reversal drugs; reporting requirement for distributions.

Who must act

Schools and local educational agencies receiving federal funds.

What happens

Increased procurement of naloxone and other opioid reversal drugs by schools, boosting demand.

Stock impact

Emergent BioSolutions manufactures Narcan (naloxone nasal spray), the leading brand. The grant program could increase school purchases, contributing to revenue growth in its naloxone product line.

Key Legislators

Rep. Ruiz, Raul [D-CA-25]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 25, 2026

Advancing Regenerative Agriculture and Strengthening American Farm Resilience

This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →